Teva Provides Update On Gemzar(R) Litigation

Main Category: Litigation / Medical Malpractice
Article Date: 06 Apr 2010 - 14:00 PDT

Current ratings for:
'Teva Provides Update On Gemzar(R) Litigation'

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. District Court for the Southern District of Indiana issued a decision yesterday on two patents for Gemzar® (gemcitabine); the compound patent expiring on November 15, 2010, and a method of use patent expiring on May 7, 2013. As to the method of use patent, the Court denied Lilly's request for an injunction on the grounds that the Eastern District of Michigan had previously found that patent invalid. Lilly has appealed that decision and oral argument is scheduled for May 7, 2010.

Teva believes it is first-to-file on that patent and thus will be able to launch a generic version of Gemzar with 180-days Hatch Waxman exclusivity when the compound patent (which the Court found valid) expires or is held invalid on appeal.

Source
Teva Pharmaceutical Industries Ltd

View drug information on Gemzar.


Article adapted by Medical News Today from original press release.
Visit our litigation / medical malpractice section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Teva Pharmaceutical Industries Ltd.. "Teva Provides Update On Gemzar(R) Litigation." Medical News Today. MediLexicon, Intl., 6 Apr. 2010. Web.
16 May. 2012. <http://www.medicalnewstoday.com/releases/184563.php>
APA
Teva Pharmaceutical Industries Ltd.. (2010, April 6). "Teva Provides Update On Gemzar(R) Litigation." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/184563.php.

Please note: If no author information is provided, the source is cited instead.


Add Your Opinion On This Article

'Teva Provides Update On Gemzar(R) Litigation'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Litigation / Medical Malpractice

Most Popular Articles



Follow Our Litigation News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Litigation / Medical Malpractice Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »